Kimera® Labs Named Semifinalist in $101 Million XPRIZE Healthspan Competition for Pioneering Innovations in Healthy Aging USA - English USA - English
The Floridant/10304323

Trending...
MIRAMAR, Fla., May 12, 2025 ~ Miami, FL - Kimera Labs, Inc., a leading company in therapeutic exosome biotechnology, has been selected as a semifinalist in the highly esteemed XPRIZE Healthspan competition. This recognition highlights Kimera's groundbreaking work in developing cutting-edge exosome-based therapeutics with the goal of significantly extending the healthy, active years of human life.

One of Kimera's key advancements is the use of Focused Ultrasound to target specific areas of the brain, allowing for enhanced uptake of exosomes. This has been demonstrated through increased numbers of exosomes being identified in regions of the hippocampus targeted by focused ultrasound. In fact, Kimera Labs has achieved a world-first by capturing an image of an exosome using novel dSTORM fluorescence microscopy techniques.

The XPRIZE was first awarded in 2004 and revolutionized problem-solving by offering a $10 million prize for private spaceflight. This sparked the commercial space industry and proved that ambitious goals, clear rules, and global participation can drive breakthrough innovation across any field.

More on The Floridant
Launched by XPRIZE in 2023, XPRIZE Healthspan is a global initiative aimed at accelerating breakthroughs in science and technology that enhance human healthspan - the period of life spent in good health. Kimera Labs' selection as a semifinalist places them among the top 40 teams chosen from over 660 applicants across 58 countries. This elite group of innovators is working towards transforming the future of aging and healthcare.

Since its establishment in 2012, Kimera Labs has gained international recognition for its pioneering clinical-grade exosome products and leadership in regenerative science. Using an FDA-approved single-donor perinatal MSC cell line, Kimera produces purified, cell-free exosome biologics at its state-of-the-art facility in Miami. This sets a new standard for purity, safety, and potency. Their flagship product, XoGlo®, has been approved for Phase I/IIa clinical trials targeting post-COVID Acute Respiratory Distress Syndrome (ARDS), showcasing Kimera's commitment to advancing validated therapies for tissue regeneration, immune modulation, and healthy aging.

"We are honored to be chosen as a semifinalist in XPRIZE Healthspan," said Dr. Duncan Ross, Founder and CEO of Kimera Labs. "This achievement is a testament to our team's decade-long dedication to scientific excellence, innovation, and our mission to harness the potential of exosomes for enhancing human health and longevity. The possibility of living past 100 years, or even 300, exists today, and the collaborations that will arise from this XPRIZE competition will help us get there."

More on The Floridant
As part of the competition, Kimera Labs has partnered with Dr. Sheldon Jordan and the Regenesis Project to combine their hyper-isolated perinatal exosome technology with low-intensity focused ultrasound targeting the brain. This innovative platform has shown promising preclinical results, which were published by the group in Nature Scientific Reports in October 2023. It has unlocked the potential to mitigate age-related diseases, promote tissue regeneration, and enhance overall vitality.

"XPRIZE Healthspan presents a pivotal opportunity for advancing global health," said Dr. Jordan. "We are thrilled to join forces with Kimera Labs in accelerating the development of transformative breakthroughs in healthy aging."

The XPRIZE Healthspan competition will conclude in 2030 with the grand prize being awarded to the team that demonstrates the most promising and scalable solution for extending healthspan and improving quality of life worldwide. With their groundbreaking work and partnerships, Kimera Labs is well-positioned as a top contender for this prestigious award.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on The Floridant